News

This drug led to 50% more weight loss than Wegovy in head-to-head study
While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...
Zepbound outperforms Wegovy in head-to-head weight loss trial
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
TipRanks on MSN2d
Eli Lilly’s Zepbound Defeats Novo Nordisk’s Wegovy Once Again
Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...
Mirage News3h
Zepbound Outduels Wegovy In Weight-loss Clinical Trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
U.S. News & World Report2d
Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs
Zepbound Beats Wegovy for Weight Loss in First Head-To ... While tirzepatide won out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity ...
EconoTimes2d
Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
Atlanta Journal-Constitution2d
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
While tirzepatide won out in what Aronne said many view as "a drag race of efficacy," both ... tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or ...